158 completed. 158 Phase 2, 15 Phase 1, 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 158 | Completed 158 |
| Phase 1 | 15 | Completed 15 |
| Phase 3 | 13 | Completed 13 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients Rutin 500 MG Oral Tablet, Fecal Calprotectin, Placebo - Ulcerative Colitis | Phase 2 | Completed | Benha University | 60 | 2025-02-22 | 2026-01-27 |
| A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis AC-101 - Ulcerative Colitis | Phase 1 / Phase 2 | Completed | Accro Bioscience (Suzhou) Limited | 25 | 2025-01-20 | 2026-10-28 |
| Trial of Mirtazapine for Depression in IBD Mirtazapine, Placebo - Major Depressive Disorder, Inflammatory Bowel Diseases | Phase 2 | Completed | King's College London | 76 | 2024-05-07 | 2026-08-19 |
| The Effects of Bromelain Supplement in Patients With Ulcerative Colitis Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 52 | 2024-04-20 | 2026-10-27 |
| A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates Arm1, Arm 2 - Ulcerative Colitis | Phase 2 | Completed | Zydus Lifesciences Limited | 24 | 2024-04-08 | 2024-12-20 |
| A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis JNJ-77242113, Placebo - Colitis, Ulcerative | Phase 2 | Completed | Janssen Research & Development, LLC | 252 | 2023-10-09 | 2026-04-13 |
| An Early Phase 2 Clinical Study of KSP-0243 KSP-0243, Placebo - Colitis, Ulcerative | Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 108 | 2023-04-27 | 2025-03-17 |
| Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis ABBV-668 - Ulcerative Colitis | Phase 2 | Completed | AbbVie | 30 | 2023-03-16 | 2025-12-23 |
| A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC MORF-057, Placebo - Inflammatory Bowel Diseases, Colitis, Ulcerative | Phase 2 | Completed | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 280 | 2022-11-21 | 2026-10-15 |
| A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease TEV-48574, Placebo - Crohn Disease, Colitis, Ulcerative | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 290 | 2022-09-30 | 2026-03-27 |
| Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications XELJANZ (tofacitinib) - Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2022-08-12 | 2026-05-07 |
| A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis Period 1 IBI112 Placebo, Period 2 IBI112 dose 3, Period 1 IBI112 dose 1 - Ulcerative Colitis (UC) | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 150 | 2022-07-01 | 2025-11-19 |
| A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC MORF-057 - Inflammatory Bowel Diseases, Colitis, Ulcerative | Phase 2 | Completed | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 39 | 2022-04-13 | 2026-03-11 |
| Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease Frondanol, Placebo - Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate | Phase 2 / Phase 3 | Completed | Mohammed Bin Rashid University of Medicine and Health Sciences | 13 | 2022-02-19 | 2024-11-20 |
| A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis BGP-014, Placebo - Ulcerative Colitis | Phase 1 / Phase 2 | Completed | BioGaia Pharma AB | 35 | 2022-02-09 | 2025-06-26 |
| GI Permeability Change in Response to Aquamin® Aquamin - Ulcerative Colitis, Healthy | Phase 2 | Completed | James Varani | 35 | 2021-11-02 | 2026-07-17 |
| Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Low Dose MT-1303, High Dose MT-1303, Placebo - Ulcerative Colitis | Phase 2 | Completed | Bausch Health Americas, Inc. | 322 | 2021-09-29 | 2025-09-09 |
| Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis | Phase 2 | Completed | Pfizer | 54 | 2021-09-10 | 2024-10-29 |
| A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo - Ulcerative Colitis | Phase 2 | Completed | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 178 | 2021-07-14 | 2026-09-01 |
| Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease Neocate Splash - Chronic Granulomatous Disease, Inflammatory Bowel Disease | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 3 | 2021-06-23 | 2025-12-11 |
Showing 20 of 158. Sign in to see all of them.
Colitis, Ulcerative (153) · Inflammatory Bowel Diseases (33) · Crohn Disease (20) · Gastrointestinal Diseases (6) · Digestive System Diseases (4) · Lymphoma, Follicular (4) · Intestinal Diseases (3) · Ulcer (3) · Cholangitis, Sclerosing (2) · Colonic Diseases (2) · Granulomatous Disease, Chronic (2) · Inflammation (2) · Mucositis (2) · Abdominal Pain (1)
Gastroenteritis (158) · Colonic Diseases (156) · Intestinal Diseases (155) · Digestive System Diseases (154) · Gastrointestinal Diseases (152) · Inflammatory Bowel Diseases (122) · Pathological Conditions, Signs and Symptoms (13) · Pathologic Processes (9) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Signs and Symptoms (5) · Hematologic Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4)
Fecal Microbiota Transplantation (9) · vedolizumab (5) · ABX464 (4) · Mesalamine (4) · etrasimod (4) · spesolimab (4) · deucravacitinib (3) · golimumab (3) · Cannabidiol (2) · Interferon beta-1a (2) · LDP-02 (2) · Methotrexate (2) · Metronidazole (2) · Sigmoidoscopy (2) · abrilumab (2)
Pfizer (6) · Bristol-Myers Squibb (5) · Janssen Research & Development, LLC (5) · AbbVie (4) · Abivax S.A. (4) · Boehringer Ingelheim (4) · Facet Biotech (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (3) · Genentech, Inc. (3) · Lakefront Biotherapeutics NV (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Shire (3) · Amgen (2) · Arena Pharmaceuticals (2) · AstraZeneca (2)
United States (77) · Poland (57) · Germany (49) · Hungary (45) · Belgium (44) · Canada (43) · Czechia (37) · France (33) · Italy (33) · United Kingdom (33) · Russia (30) · Netherlands (29) · Ukraine (29) · Spain (27) · Israel (26)
Arena CT.gov Administrator (2) · Christa S Zerbe, M.D. (2) · Hans Israelsen, PhD (2) · Wolfgang Stremmel, Professor (2)
PMID 30721964, PMID 26893500, PMID 39778975, PMID 16984503, PMID 17920064, PMID 17975182, PMID 18325386, PMID 18623174, PMID 19145731, PMID 19714757, PMID 19885903, PMID 20048683, PMID 20413687, PMID 21471566, PMID 21871249, PMID 21929562, PMID 22549092, PMID 22605655, PMID 22894574, PMID 23078909, PMID 23461895, PMID 23714676, PMID 23735746, PMID 23846486, PMID 23872668, PMID 23909727, PMID 24814090, PMID 25185797, PMID 25192498, PMID 25304132, PMID 25567115, PMID 25651782, PMID 25836986, PMID 25857665, PMID 25996351, PMID 26070003, PMID 26376350, PMID 26478682, PMID 26632520, PMID 26721935, PMID 26933886, PMID 27415795, PMID 28214091, PMID 28349233, PMID 28527704, PMID 29538683, PMID 29850873, PMID 29917064, PMID 29964043, PMID 29981298
2016 (9), 2017 (7), 2018 (6), 2023 (3), 2014 (2), 2015 (2), 2019 (2), 2009 (1), K23DK073750 (1), R01DK059961 (1), R01DK128257 (1), U01DK092239 (1)